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Abstract
Background: Despite numerous in vivo evidences that Tumor Necrosis Factor Receptor-Associated Factor 4 (TRAF4) plays a
key biological function, how it works at the cellular and molecular level remains elusive.
Methodology/Principal Findings: In the present study, we show using immunofluorescence and immuohistochemistry that
TRAF4 is a novel player at the tight junctions (TJs). TRAF4 is connected to assembled TJs in confluent epithelial cells, but
accumulates in the cytoplasm and/or nucleus when TJs are open in isolated cells or EGTA-treated confluent cells. In vivo,
TRAF4 is consistently found at TJs in normal human mammary epithelia as well as in well-differentiated in situ carcinomas.
In contrast, TRAF4 is never localized at the plasma membrane of poorly-differentiated invasive carcinomas devoid of correct
TJs, but is observed in the cytoplasm and/or nucleus of the cancer cells. Moreover, TRAF4 TJ subcellular localization is
remarkably dynamic. Fluorescence recovery after photobleaching (FRAP) experiments show that TRAF4 is highly mobile and
shuttles between TJs and the cytoplasm. Finally, we show that intracellular TRAF4 potentiates ERK1/2 phosphorylation in
proliferating HeLa cells, an epithelial cell line known to be devoid of TJs.
Conclusions/Significance: Collectively, our data strongly support the new concept of TJs as a dynamic structure. Moreover,
our results implicate TRAF4 in one of the emerging TJ-dependent signaling pathways that responds to cell polarity by
regulating the cell proliferation/differentiation balance, and subsequently epithelium homeostasis. Drastic phenotypes or
lethality in TRAF4-deficient mice and drosophila strongly argue in favor of such a function.
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Introduction
The compartmentalization-oriented architecture of the epithelia
is a basic property of higher life forms. As cells assemble to form
tissues, the organization of the plasma membrane becomes
increasingly complex. Epithelial cells interact with each other via
specialized cellular junctions that are critical for the normal
development and function of the epithelia (reviewed in [1,2]).
They include adherens junctions (AJ), desmosomes and tight
junctions (TJ). TJs encircle cells at the apical end of the lateral
membrane to form a paracellular diffusion barrier that regulates
epithelial permeability, and an intramembrane diffusion barrier
which restricts the apico-basolateral diffusion of membrane
components. There are a plethora of mechanisms that control
or are controlled by TJs. Thus, TJs have been shown to contribute
to epithelial biogenesis and function by regulating cell prolifera-
tion, differentiation and polarisation. Moreover, it has been
proposed that the assembly state of TJs acts as a sensor for cell
density. This implies that TJs can regulate downstream signaling
pathways via a multiprotein complex network that constitute the
TJ plaque, a process just beginning to be understood [3].
The Tumor Necrosis Factor Receptor-Associated Factor family
is composed of 6 members that share a TRAF domain (TRAF1 to
TRAF6). They are adaptor/scaffold molecules that mainly
interact with members of the interleukin-receptor (ILRs) or tumor
necrosis factor-receptor (TNFRs) families and exhibit functions
mostly in the immune system [4,5]. However, TRAF4 only weakly
interacts with 3 members of TNF-R family, namely the p75
neurotrophin receptor (p75-NGFR), the lymphotoxin-beta recep-
tor (LTa ˆR), and the glucocorticoid-induced TNF-R (GITR), and
its involvement in immune system remains elusive (reviewed in
[6]). These data suggest that TRAF4 might rather be implicated in
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TRAF4 plays a key function. Indeed, mouse TRAF4 deficiency is
embryonic lethal in approximately one third of the homozygote
mutants. Surviving animals manifest numerous alterations,
including important malformations in the trachea and the axial
skeleton (ribs, sternum, tail), and defects in the neural tube closure
giving rise to spina bifida phenotypes [7]. Similarly, a null allele for
DTRAF1, the drosophila homologue of TRAF4, is embryonic
lethal for drosophila. DTRAF1 is indispensable for the develop-
ment of imaginal eye discs and the formation of a correct
photosensory neuronal array in the brain hemisphere [8].
Moreover, in the adult, constitutive basal level of TRAF4
expression is observed in most tissues, suggesting a generic
biological function for this protein. Finally, TRAF4 has also been
observed to be overexpressed in various human cancers [9,10].
Here, we show in vitro and in vivo that TRAF4 functions at the
discrete TJ submembrane domain. Indeed, TRAF4 is observed at
the TJ multiprotein complex areas. Moreover, fluorescence recovery
after photobleaching (FRAP) analysis show that association of
TRAF4 with the TJ is not a stable event but a highly dynamic
process. Thus, TRAF4 is a shuttling protein. These results prompted
us to investigate the ability of TRAF4 to activate the ERK1/2 MAP
kinase and Akt signaling pathways which have been shown to be
down-regulated by functional TJs. When not associated with TJs,
TRAF4 acts to increase ERK1/2 phosphorylation in proliferating
but not confluent cells. Collectively, our results allow us to assign a
biological function to the TRAF4 scaffold protein in favoring the
ERK1/2 signalling pathway in response to cell polarity damage.
Results
Endogenous TRAF4 is found in the plasma membrane,
cytoplasmic and nuclear fractions of normal/
immortalized human MCF10A confluent cells
To date, the sub-cellular TRAF4 localization pattern remains
debated. In in vitro experiments, TRAF4 has been reported to
localize at the cell membrane, in the cytoplasm, in perinuclear
areas or in the nuclei (reviewed in [6]). In carcinomas, its
localization is cytoplasmic and/or nuclear [10]. More importantly,
very few data concerning endogenous TRAF4 sub-cellular
localization under normal conditions are available. In order to
address this question, we performed a stringent fractionation assay
(see material and methods) to separate the membrane, cytoplasmic
and nuclear compartments from confluent MCF10A cells, derived
from human normal/immortalized mammary epithelial cells.
Extracts were loaded on SDS-PAGE and the presence of
endogenous TRAF4 was tested by Western blot analysis using
the 2H1 mouse monoclonal antibody as previously described [7].
Antibodies specific for E-cadherin, a marker for plasma membrane
and cytoskeleton [11], and the serine/arginine-rich (SR) protein
9G8, a splicing factor that is mainly observed in nuclei [12] were
used as controls. TRAF4 was observed in all fractions (Figure 1).
As expected, E-cadherin and 9G8 were detected only in the
membrane and nuclear extracts, respectively.
Thus, endogenous TRAF4 is associated with the plasma
membrane, cytoplasmic and nuclear sub-cellular fractions under
normal conditions.
The TRAF domain is responsible for TRAF4 plasma
membrane and nuclear addressing
We then investigated which conserved domains within TRAF4
could be responsible for these localizations. The TRAF4 protein
contains 1 RING, 3 CARTs and 1 TRAF domains [9]. Full-length
TRAF4 (AA1-AA470, construct A) and 2 deletion mutants -
mutant B (AA1–AA281) corresponding to the amino-terminal part
of TRAF4 containing the RING and the 3 CART domains, and
mutant C (AA282–AA470) corresponding to the carboxy-terminal
part of TRAF4 containing the TRAF domain - were fused to the
Flag epitope (Figure 2, left part). These constructs were transiently
transfected in various cell lines and the sub-cellular localization of
their products were evaluated using the anti-flag antibody using
confocal microscopy (Figure 2, right part). Full-length TRAF4 was
located at the plasma membrane, cytoplasm and nucleus,
indicating that the 3 TRAF4 localizations are not exclusive, at
least in transfected cells. Mutant B devoid of the TRAF domain
was only found in the cytoplasm. In contrast, mutant C which
contains only the TRAF domain showed membrane and nuclear
localization, but was absent from the cytoplasm.
Collectively, these results indicate that the TRAF domain is
required to address TRAF4 to the plasma membrane and the
nucleus.
Cell-cell contacts govern the membrane localization of
TRAF4
To visualize endogenous TRAF4 in cells, we first performed
immunofluorescence analysis (IF) of confluent MCF10A cells using
the 2H1 antibody, using classical fluorescence microscopy.
TRAF4 was observed mainly in the cytoplasm and at the plasma
membrane (Figure 3 A). In parallel, we performed similar
experiments using MCF10A cells transiently transfected with a
full-lenght TRAF4 fused to the Flag epitope at its amino-terminal
(Flag-TRAF4 ; construct A). The pattern of Flag-TRAF4 was
similar to that of endogeneous TRAF4 with the addition of a low
nuclear staining (Figure 3 B). We then studied TRAF4 localization
in isolated MCF10A cells present in non-confluent culture. In this
case, neither endogenous nor transfected Flag-TRAF4 proteins
were found at the plasma membrane (Figure 3 C and D), showing
that cell-cell contacts are required for the recruitment of TRAF4
to the membrane. Moreover, a stronger cytoplasmic patched
staining was observed in Flag-TRAF4 transfected cells (Figure 3D).
This is probably due to excess TRAF4 protein, since similar
staining was observed in vivo in human invasive carcinomas
overexpressing TRAF4 (see below and [9,10]).
Thus, TRAF4 localizes to the plasma membrane only when
cells are confluent suggesting that TRAF4 function might be
related to intercellular junctions.
Figure 1. Subcellular localization of endogenous TRAF4 in
fractionated extracts of MCF10A cells. Protein fractionation from
confluent normal/immortalized MCF10A cells was performed using the
ProteoExtract Subcellular Proteome Extraction kit in order to separate
cytoplasmic, membrane, and nuclear proteins. These fractions were
analyzed by western blot using anti-E-cadherin, anti-9G8 and 2H1 anti-
TRAF4 antibodies. TRAF4 is observed in all fractions whereas the
membrane specific E-cadherin and nucleus specific 9G8 are only seen in
membrane and nuclear fraction, as expected.
doi:10.1371/journal.pone.0003518.g001
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To determine if TRAF4 binds a particular junction, we
performed an extensive colocalization study of TRAF4 with
markers of cell-cell junctions. Confluent monolayers of MCF7 cells
(well-differentiated human breast cancer cells) were tested for the
presence of transiently-transfected human Flag-TRAF4 at AJs
(Figure 4 A), desmosomes (Figure 4 B) and TJs (Figure 4 C), as
identified by their respective markers E-cadherin, desmoplakin
and occludin using appropriate antibodies and fluorescence
confocal microscopy. E-cadherin, desmoplakin and occludin
staining partially overlapped. This is consistent with reports
showing that AJs can be concentrated close to TJs, or be
distributed over the entire lateral membrane like desmosomes
[13,14]. We observed that Flag-TRAF4 was not randomly
distributed along the plasma membrane, but partially colocalized
with the E-cadherin, desmoplakin and occludin. The best
colocalization pattern was observed with occludin (Figure 4 C
and data not shown), suggesting that TRAF4 localizes to TJs.
Since these experiments evaluated only exogenous Flag-TRAF4,
we checked for sub-membrane localization of endogenous
TRAF4. Using the 2H1 antibody on human MCF7 cells, IF
staining showed that endogenous TRAF4 colocalized with
endogenous occludin at the TJs (Figure 4 D). Both yz- and xz-
scans showed respectively similar punctual and linear staining for
TRAF4 and occludin at the apical part of the lateral plasma
membrane of confluent cells, typical of TJs,
TJs are composed of a multiprotein complex which includes
transmembrane proteins (ie : occludin), and supra-membrane
proteins (ie : zonula occludens 1 (ZO1) and ZO2), recruited by the
former and which constitute the cytoplasmic plaque [15].
Localization of TRAF4 at the TJ was further confirmed in
colocalization experiments with ZO1 in MCF7 cells. IF staining
showed that endogenous TRAF4 colocalized with endogenous
ZO1 at the TJs. As expected, both xz- and yz-scans showed similar
staining for TRAF4 and ZO1 at the TJs (Figure 4 E). Finally,
similar results were obtained for 2 normal epithelial cell lines: in
transient transfection experiments using Madin-Darby Canine
Kidney (MDCK) cells which are known to become polarized at
confluency [16], and in human MCF10A cells (data not shown).
Thus, in several epithelial cell types, normal or malignant, we
observed that TRAF4 is not homogeneously distributed along the
plasma membrane but accumulates at the TJs of contacting
neighboring cells.
TRAF4 is present at the TJ multiprotein complex in
normal human epithelia
We studied the in vivo submembrane distribution of endoge-
nous TRAF4 in the polarized epithelial cells that form the normal
human mammary epithelium. The colocalization of ZO1, ZO2
and occludin, and E-cadherin were performed on adjacent serial
mammary gland sections using immunofluorescence (IF) confocal
microscopy to visualize TJs and AJs respectively (Figure 5 A–D).
The TRAF4 pattern was similar to those of ZO1, ZO2 and
occludin. Thus, on mammary duct transversal sections, they
showed punctate staining at epithelial cell-cell contacts, in the
apical part of the lateral membrane. The other parts of the plasma
Figure 2. Plasma membrane, cytoplasm and nucleus addressing of TRAF4 deletion mutants. Left part: Schematic representation of the 3
constructs coupled to Flag. A: full-length TRAF4 (AA1-470), B (AA1-281) and C (AA282-470). Right part of the figure represents image projection of
several confocal sections. Mutant C containing the TRAF domain only was addressed to the plasma membrane and nucleus, like the full-length TRAF4
protein, but was absent from the cytoplasm. In contrast, mutant B devoid of the TRAF domain was only addressed to the cytoplasm. AA: amino acid.
doi:10.1371/journal.pone.0003518.g002
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cadherin extended to the entire lateral plasma membrane (Figure 5
D). The colocalization of TRAF4 with ZO1, ZO2, and most
notably occludin, a transmembrane protein specific of TJs,
indicates that TRAF4 is present at the TJ multiprotein plaque.
Thus, in vivo, TRAF4 is not randomly distributed along the
plasma membrane but is restricted to the TJ submembrane
domain in normal human epithelia.
TRAF4 is addressed to assembled TJs
Cell-cell junctions are primordial players in tissue differentiation
and homeostasis. Epithelial tumor progression involves a series of
cumulative alterations. Invasive and migratory properties should
notably be acquired, enabling cells to pass from a sessile to a motile
phenotype and to ultimately metastasize. During this process,
disruption of cell-cell adhesion and loss of functional junctions is a
major event. Previous studies of invasive tumors did not report
TRAF4 plasma membrane localization, but cytoplasmic in a large
majority of cases and/or nuclear localization in around 20% of
cases [10]. Thus, we hypothesized that TRAF4 localizes to the
plasma membrane only when TJs are correctly assembled. To test
this hypothesis we forced TJ alteration in confluent MCF7 cells
transiently transfected with human Flag-TRAF4 grown in the
presence of EGTA, a Ca2+ chelating agent that disrupts TJs [17].
In these cells, TRAF4 became cytoplasmic and nuclear (Figure 6 A
and B). By contrast, in the same condition, ZO1 remained
associated with the plasma membrane although its honeycomb
pattern was lost (Figure 6 B), similar to previous reports [17].
Similarly, in EGTA-treated confluent monolayer of MCF10A
cells, endogenous TRAF4 staining became mainly cytoplasmic
and nuclear, and no plasma membrane staining was observed
(Figure 6 C, right part). As an additional control, we analyzed the
localization of TRAF4 in HeLa cells which are devoid of TJs, even
when confluent [18]. In this cell line, TRAF4 was never observed
at the plasma membrane, even when overexpressing Flag-TRAF4
(Figure 6 D). Finally, under optical microscopy, in in situ breast
primary tumors exhibiting well-differentiated features, although
the epithelial cells are malignant we observed a TRAF4 TJ pattern
at the remaining cell-cell contacts (Figure 6 E), similar to that
shown in normal epithelium (Figure 5), whereas invasive
carcinomas are totally devoid of such staining (Figures 6 F and
G), but exhibit cytoplasmic and/or nuclear staining [9,10].
Collectively, our results indicate that TRAF4 is connected to the
plasma membrane with assembled TJs, suggesting a TJ-related
function for this protein.
TRAF4 connection at the TJs is higly dynamic
FRAP studies offer new insight into basic biological mechanisms
[19], as they permit the measurement of force-dependent
alterations in molecular binding and unbinding of individual
proteins in situ in the physical context of the living cytoplasm [20].
The combination of time-lapse imaging with FRAP enables the
analysis of the kinetic properties of a given protein in living cells.
As photobleaching is an irreversible process, fluorescence recovery
comes from proteins already present in the cell. Thus, the recovery
kinetics are dependent on the mobility of the protein of interest.
Slow recovery indicates low mobility. Thus, we ask whether TJ
association of TRAF4 is stable, or whether TRAF4 can
dynamically move in and out of TJs. We therefore generated a
EYFP tagged TRAF4 fluorescent protein (EYFP-TRAF4) to test
the kinetics of TRAF4 recruitment to the TJs using the FRAP
technique. MDCK cells were transfected with EYFP-TRAF4,
allowed to polarize during 72 hours after transfection and then
subjected to FRAP. In order to avoid visualization of intramem-
brane protein movements, all of the TJs of the cell were bleached.
FRAP experiments showed that EYFP-TRAF4 rapidly recovers
within the bleached area. Thus 50% recovery (t1/2) is observed in
8.3 seconds indicating that TRAF4 is a highly mobile protein. The
recovery curve reached a plateau at 75% of the initial fluorescence
of the pre-bleached area, indicating that only a small proportion of
the TRAF4 protein was immobile (immobile fraction=24%)
(Figure 7 A). The cytoplasmic fluorescence intensity variations
were also monitored in either bleached or unbleached cells.
Interestingly, we showed that in parallel to the gain of fluorescence
in TJs after the bleach, the fluorescence of the cytoplasm
decreased. These results indicate an exchange of TRAF4
molecules between the cytoplasm and the TJs (Figure 7 B, and
Movies S1 and S2). The cytoplasmic fluorescence intensity
remains constant in the unbleached cells.
These experiments reveal that the TJ association of TRAF4 in
epithelial cells is highly dynamic and that TRAF4 shuttles between
TJs and cytoplasm.
Intracellular TRAF4 potentiates ERK1/2 MAPKinase
mediated signals in proliferating cells
Previous studies have associated TJ function with the extracel-
lular signal-regulated kinase 1 and 2 (ERK1/2) mitogen-activated
protein kinase (MAPK) and Akt/PKB (protein kinase B) pathways
[3,21]. It has been proposed that TJs may decrease the activity of
these pathways most probably via recruited proteins. We
hypothesized that TRAF4 might participate in this process when
Figure 3. TRAF4 localization depending on cell density. IF
analyses of the localization of endogenous TRAF4 (A and C) or
transiently transfected Flag-TRAF4 (B and D) in confluent (A and B) or
sparsely populated (C and D) MCF10A cells. Cells were fixed,
permeabilized and stained using 2H1 anti-TRAF4 antibody (A and C)
or an anti-Flag antibody (B and D), respectively. Nuclei were stained
using Hoechst-33258 (blue). Localization of endogenous and exoge-
nous TRAF4 at the plasma membrane is lost in sparse cells, and TRAF4 is
mostly cytoplasmic. A weak nuclear staining is observed in cells
expressing Flag-TRAF4. Thus, TRAF4 is only present at the plasma
membrane when cells are confluent. Analyses were performed using a
fluorescence microscope (Leica DMLB 30T, Leica Micro system, Wetzlar
Germany). Magnification 636.
doi:10.1371/journal.pone.0003518.g003
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Co-staining was performed using an anti-Flag antibody in combination with either anti-E-cadherin (panel A), anti-desmoplakin (panel B), or anti-
occludin (panel C) antibodies specific for AJs, desmosomes, and TJs, respectively. A partial colocalization of TRAF4 with the 3 proteins was observed,
the highest overlapping rate was observed with occludin. (D) : Co-staining of endogenous TRAF4 and occludin in MCF7 cells using the 2H1 anti-
TRAF4 and anti-occludin antibodies. xz- and yz-scans show the expected linear and punctual localization of human TJ-related protein occludin (red) in
sections of 0.4 mm from the apical pole of the cell. TRAF4 (green) exhibited similar staining. (E) : Co-staining of endogenous TRAF4 (green) and TJ-
related protein ZO1 (red) in MCF7 cells using the 2H1 anti-TRAF4 and anti-ZO1 antibodies. There is a perfect colocalization of these proteins.
Collectively, these data show that, at the plasma membrane, TRAF4 is restricted to the TJs. For all experiments, nuclei were stained using Hoechst-
33258 (blue), and microscopy analysis was performed using a Zeiss Axiovert 100 M confocal laser scanning microscope equipped with LSM5 Pascal
(Jena, Germany). The figure represents image projection of several confocal sections. Magnification : A–C , 406; D and E, 636.
doi:10.1371/journal.pone.0003518.g004
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test due to the highly dynamic manner of TRAF4 shuttling. Since
these pathways participate in the regulation of cell proliferation/
differentiation [22], we tested the ability of overexpressed Flag-
TRAF4 (2.5 mg) to increase ERK1/2 and Akt signalling at 2
different cell densities: 40% (proliferating cells) and 100%
confluent (resting cells). Phosphorylation of ERK1/2 and Akt
was tested by Western blots using antibodies specifically directed
against the phosphorylated forms of ERK1/2 and Akt. Total
ERK1/2 and Akt were detected using specific pan-antibodies. The
Flag-TRAF4 was visualized using the 2H1 anti-TRAF4 antibody.
As it is very difficult to obtain epithelial cells completely devoid of
TJs, even in low density culture conditions (these cells frequently
form ilots), we used HeLa cells that, although epithelial in origin,
are devoid of TJs [18] and never show TRAF4 at their plasma
membrane, even when overexpressed (Figure 6 D). This allowed
us to discard any possibility of TRAF4 association with TJs, and to
test the effect of intracellular TRAF4. Akt was not phosphorylated
in all cases (data not shown). However, we observed increased
phosphorylation of ERK1/2 in the presence of TRAF4 in low-
density cells, but not in confluent cells (Figure 8 A). When we
transfected increasing Flag-TRAF4 amounts (1, 5 and 10 mg) into
low-density cells, ERK1/2 phosphorylation was enhanced in a
TRAF4 dose-dependent manner (Figure 8 B). These results
indicate that, although unable to induce ERK1/2 phosphorylation
in resting cells, TRAF4 potentiates the ERK1/2 signaling pathway
in proliferating HeLa cells.
Thus, when not associated with TJs, TRAF4 increases the
ERK1/2 MAPKinase signaling pathway in non-confluent and
proliferating cells.
Discussion
While other TRAFs have been mostly implicated in the immune
system as adaptor proteins of TNF-R and IL-R [4,5], the TRAF4
biological function has remained elusive [6]. Our present data
provide in vitro and in vivo evidence that TRAF4 function is
related to epithelial cell polarity and epithelium homeostasis.
Using several cell lines and human breast tissues, we showed
that TRAF4 localizes to a remarkable subdomain of the plasma
Figure 5. TRAF4 localization at the plasma membrane of normal human mammary epithelium. (A–D): TRAF4 (green) and occludin (A,
red), ZO1 (B, red), ZO2 (C, red) or E-cadherin (D, red) were co-labelled on paraffin embedded sections of human normal breast ducts. Images are
confocal transverse sections. Nuclei were stained using Hoechst-33258 (blue). Strong focal staining at the apical part of the plasma membrane which
correspond to TJs is observed for TRAF4, occludin, ZO1 and ZO2. In contrast, E-cadherin localizes along the entire lateral plasma membrane. Thus,
TRAF4 is seen at the TJs sealing neighboring cells in normal mammary ducts. TRAF4 cytoplasmic staining is also observed. Scale bars: 10 mm.
doi:10.1371/journal.pone.0003518.g005
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TJs. TJs are intercellular adhesion structures that are indispensable
for correct epithelium organization. TJs assemble when epithelial
cells reach high cell densities and adhere to each other, giving rise
to well organized and differentiated functional polarized tissues.
We showed that the TRAF domain of TRAF4 is indispensable for
this localization. This particular sub-membrane localization of
TRAF4 was unexpected as none of the putative TRAF4 partners
identified until now corresponds to proteins already reported to be
related to TJs [2,23,24]. Thus, using in vitro experiments, more
than 20 putative TRAF4 partners have been identified. These
include the p70S6K ser/thr kinase, Misshapen (Msn) and Pelle
(the drosophila homologues of mammalian Nck-interacting kinase
(NIK) and Interleukin-1 receptor-associated kinase (IRAK),
respectively), the MAPKinase MEKK4, the p47phox adapter
subunit of the NAD(P)H oxidase, nuclear proteases, apoptosis
Figure 6. TRAF4 localization in disrupted TJs. (A–B): Chemical disruption of TJs : Confluent MCF7 cells transiently transfected with Flag-TRAF4
were treated for 2 hours with (B) or without (A) EGTA. Cells were fixed and stained using anti-Flag and anti-ZO1 antibodies. After EGTA incubation,
most TJs were disrupted with concomitant loss of localized membrane staining for TRAF4. Moreover, TRAF4 and ZO1 no longer colocalize in the
absence of TJs since, although it loses its honeycomb pattern, ZO1 remains partially associated with the plasma membrane whereas TRAF4 becomes
cytoplasmic. (C) : similar experiments were performed using confluent MCF10A and 2H1 anti-TRAF4 antibody. While untreated cells show a
characteristic honeycomb staining pattern for TRAF4 (left part), endogenous TRAF4 membrane localization is lost after EGTA-treatment (right part).
For experiments (A–C), nuclei were stained using Hoechst-33258 (blue), and microscopy analysis was performed using a fluorescence microscope
(Leica DMLB 30T, Leica Micro system, Wetzlar Germany) (C, magnification 636), or a Zeiss Axiovert 100 M confocal laser scanning microscope
equipped with LSM5 Pascal (Jena, Germany) (A and B, magnification 406). (D): Confluent HeLa cells transiently transfected with Flag-TRAF4 (red).
Note the absence of TRAF4 at the plasma membrane (magnification 806). (E) : IH analysis of endogenous TRAF4 expression in human well-
differentiated in situ breast carcinomas. 2H1 anti-TRAF4 antibody was used on paraffin embedded sections. Focal staining is observed in the epithelial
structures at the apical part of the lateral sides of the plasma membrane of the epithelial cells which correspond to TJs (arrow heads). Thus, TRAF4
remains at the TJs sealing neighboring cells in well-differentiated in situ carcinomas. (F,G): Similar IH analysis of endogenous TRAF4 expression in
human invasive breast carcinomas known to be devoid of functional TJs [10]. No TRAF4 staining was observed at the plasma membrane but strong
diffuse or patched staining was seen in the cytoplasm. Thus, assembled TJs are required for TRAF4 plasma membrane localization. Magnification: E,
6200; F and G, 6150.
doi:10.1371/journal.pone.0003518.g006
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has yet to be established.
Functional TJs are associated with well-differentiated non-
proliferating cells. TJs are normally disrupted to allow cell division,
tissue renewal and wound healing. We established that TRAF4 is
only connected to assembled TJs. While TRAF4 is clearly
associated with TJs in confluent cells, no TRAF4 staining remains
at the cell plasma membrane in isolated cells nor in confluent cells
after EGTA-induced TJ disruption. Similarly in vivo, TRAF4 is
observed at the TJs sealing epithelial cells of normal mammary
epithelium. Loss of cell-cell adhesion and TJ alteration occurs as
epithelial tumors progress [25]. Moreover, fully formed TJs in
high-density cells have been shown to function as suppressors of
signaling pathways that stimulate proliferation and inhibit
differentiation, thereby contributing to epithelium biogenesis
and/or homeostasis [23]. Interestingly, aggressive malignant
tumors never exhibit membrane TRAF4 staining [9,10]. Howev-
er, in in situ tumors which have conserved some structural
epithelial organization and therefore TJs, this TRAF4 staining
remains. Together these data indicate that TRAF4 is connected to
assembled TJs, but not to scattered TJ proteins.
The visualization of proteins by IH reveals a steady-state picture
with a defined distribution within the cell. However, protein
mobility within a cell is of key importance since it is an essential
prerequisite for numerous cellular functions [26]. We therefore
analyzed TRAF4 TJ addressing in FRAP experiments to track
intracellular events in living cells. Fluorescence recovery occurs
very rapidly, indicating that TRAF4 is a highly mobile protein that
exchanges between membrane and intracellular pools. Moreover,
cytoplasmic fluorescence decreased over time in the bleached cells
strongly supporting a shuttling function for TRAF4 between the
TJs and the cytoplasm. These data are consistent with the recent
report showing that the TJ protein complex undergoes rapid and
continuous molecular remodeling [27]. Indeed, until now, the TJ
was widely viewed as a static structure. Our data strongly support
the new concept of TJ as a dynamic structure.
There is a growing evidence that TJ-related protein function
can depend on their dual localization both at TJs and nucleus [26].
Most of them have been linked to the regulation of transcription or
to RNA processing [23]. ZO1-associated nucleic acid-binding
protein (ZONAB), a transcription factor required for G1/S phase
progression, is TJ-associated in confluent cell cultures but
accumulates in nucleus when cells are dispersed [13]. Thus,
ZONAB sequestration by functional TJs reduces cell proliferation.
ZO1 re-localization has been shown to be associated with
induction of invasion in pancreatic cancer cells [28], or induction
of matrix metalloproteinase 14 transcription [29]. ZO2 interacts
with the nuclear ribonucleoprotein (hnRNP) Scaffold Attachment
Factor B (SAF-B) in proliferating cells [30]. The mechanism of
their shuttling is not clearly established. Since TRAF4 is also
observed in the nucleus, most notably in invasive malignant
tumors known to be devoid of TJs, a similar shuttling between TJs
Figure 7. FRAP analysis of TRAF4 mobility into TJs. MDCK cells transfected with EYFP-TRAF4 for 72 hours were analyzed by FRAP. (A): One
representative cell expressing EYFP-TRAF4 is shown at different time points (time in seconds). All TJs were bleached and pictures were taken every
3.3 s. The bleach zone is highlighted with white arrows. Graphical representation of fluorescence recovery pattern is shown on the right (n=14). The
bleach period is highlighted by the gray rectangle. A fitted curve is shown. Calculated half recovery time (t1/2) is 8.3 s and the mobile fraction is 76%.
(B): cytoplasmic fluorescence decay in 1 bleached (lower) and 1 unbleached (upper) EYFP-TRAF4 expressing cell. Fluorescence intensity was measured
in similar cytoplasmic areas (blue and green squares) of the unbleached and bleached cell respectively. The fluorescence intensity over time is shown
for these two areas on the right. While the fluorescence intensity remains constant in the unbleached cell, it decreases over time in the bleached cell,
showing that cytoplasmic EYFP-TRAF4 molecules are mobilized to the bleached area during recovery. Thus TRAF4 shuttles very rapidly between the
cytoplasm and TJs.
doi:10.1371/journal.pone.0003518.g007
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between TJs and nucleus is compatible with its absence at the
plasma membrane and its nuclear accumulation in 20% of various
types of cancer cells [10], and supports the idea that TRAF4 might
contribute to maintaining tissue homeostasis by regulating
proliferation/differentiation processes.
How TJ complexes actually signal and maintain cell polariza-
tion is still poorly understood. It has been proposed that the
occludin TJ compound can directly interact with phosphatidyli-
nositol-3 kinase (PI3K) to allow the phosphorylation of phospha-
tidylinositol 2 phosphate (PIP2) into PIP3, and link TJs to lipid
signaling, and indirectly, to the Akt pathway [23]. However,
TRAF4 overexpression does not induce Akt phosphorylation,
indicating that TRAF4 is not involved in this pathway. TJs have
also been reported to be connected to Raf-1 signaling since an
overexpression of occludin reverses Raf-1-mediated cell transfor-
mation [21]. In numerous human cancers, there is a direct
correlation between loss of TJs, deregulation of Ras signaling, and
cancer progression and metastasis [23]. The best known effectors
of Ras are the Raf kinases which stimulate cell cycle entry via
ERK/MAPkinase activation, leading to anarchic cell proliferation
in cancers. Interestingly, we showed in non-confluent epithelial
HeLa cells devoid of TJs that TRAF4 overexpression increases
ERK1/2 phosphorylation in a dose-dependent manner, indicating
that cytoplasmic TRAF4 can enhance this MAPK signaling.
Similar TRAF4 activation of ERK1/2 MAPK was recently
reported in endothelial cells [31]. It is becoming more and more
evident that ERK signaling cascade plays a role in the regulation
of various cellular processes depending on cooperating mecha-
nisms not fully understood to date (reviewed in [22]). In this
context, TRAF4 might contribute to signaling events via the ERK
pathway when it is not engaged at TJs. Such a function is
consistent with the putative function of TRAF4 as an oncogene
[10,32,33]. Thus, TRAF4 activity might be negatively regulated
when connected to TJs. Since TRAF4 is never addressed to the
plasma membrane in invasive carcinomas, it can be hypothesized
that this function on ERK might be constitutively turn on in
malignant conditions.
In conclusion, our collective results allow us to propose a
cellular function for the TRAF4 scaffold protein in mediating
plasma membrane dynamics in response to cell polarity damage to
maintain cell proliferation/differentiation balance and therefore
epithelium homeostasis. Such a function is consistent with the fact
that TRAF4 TJ localization is lost in favor of the cytoplasm and/
or nucleus in poorly-differentiated invasive tumors [10]. It is also
consistent with the hypothesis of a generic function for TRAF4 in
tissue proliferation/differentiation and organ ontogenesis during
embryogenesis [6]. Indeed, it has been shown that TJ formation
during development is critical for embryonic patterning and
organization [34] while TRAF4-deficient mice [7] and drosophila
present drastic phenotypes or lethality [8].
Materials and Methods
Cell culture
The normal/immortalized mammary epithelial MCF10A cell
line was a kind gift of M. Polette [35]. The cancer epithelial cell
lines MCF7 and HeLa, as well as the normal/immortalized canine
epithelial cell line MDCK, are described and available at the
American Type Culture Collection (ATCC, Rockville, MD). Cells
were routinely maintained in our laboratory and cultured as
recommended.
In order to disrupt TJs, Ca
2+ chelation was performed by
treating confluent MCF10A or MCF7 cells with 2.5 mM EGTA
for 2 hours. EGTA was then removed and cells were fixed and
stained using appropriate antibodies to visualize TRAF4, Flag-
TRAF4 and ZO1.
TRAF4 subcellular distribution
To examine the normal subcellular distribution of endogenous
TRAF4, confluent MCF10A cells were fractionated using the
ProteoExtract Subcellular Proteome Extraction kit (Calbiochem,
La Jolla, CA). The proteins present in supernatant were quantified
by the Bradford technique using a detergent-compatible protein
assay (Bio-Rad), and equivalent total protein amounts were loaded
on 10% SDS-PAGE gels, and electrotransferred to nitrocellulose
Figure 8. Effect of cytoplasmic TRAF4 on ERK signaling pathway.
(A): 40% and 100% confluent HeLa cells that never form TJs (Figure 6 D)
were transfected with the Flag-TRAF4 expression vector (2.5 mg) or an
empty vector (2.5 mg). Twenty-four hours after transfection, proteinswere
extracted, and analyzed by immunoblotting with antibody for phospho-
ERK1/2. Total amounts of ERK1/2 were evaluated by reprobing the blots
with pan-ERK antibody. TRAF4 expression was tested using 2H1 anti-
TRAF4antibody.ActivationofERK1/2is dependent oncell confluency.(B):
a similar experiment in non-confluent cell condition using increasing
amounts of the Flag-TRAF4 expression vector (1 mg, 5 mgo r1 0mg).
Activation of ERK1/2 is dependent on the amounts of transfected Flag-
TRAF4. (A and B): a representative western blot from four independent
experiments is shown. Thus, TRAF4 favors ERK1/2 MAPK activation in
proliferating HeLa cells.
doi:10.1371/journal.pone.0003518.g008
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were blocked in PBS containing 3% fat-free milk and 0.1% Tween
20. The mouse monoclonal anti-TRAF4 2H1 antibody (1/5000;
IGBMC, [7]), the rat monoclonal anti-E-cadherin antibody (1/
400; Boehringer, Mannheim, Germany) and rabbit polyclonal
anti-9G8 antibody (1/1000 ; kind gift of R. Gattoni, IGBMC,
[12]) were used as primary antibodies. Horseradish peroxidase-
conjugated AffiniPure goat anti-mouse, donkey anti-rat, or goat
anti-rabbit (Jackson Immunoresearch, West Grove, PA) were used
as secondary antibodies at dilution of 1/10000. Protein-antibody
complexes were visualized by an enhanced chemiluminescence
detection system (SuperSignal West Pico, Pierce, Pockford, IL).
ERK and AKT analysis
To test the ability of TRAF4 to activate ERK1/2 and Akt, HeLa
cells were plated in 100 mm dishes at low (40%) or high (100%) cell
density and transiently transfected with appropriate amounts of the
Flag-TRAF4 pRK5 expression vector, or empty vector as control,
using the JetPEI
TM transfection reagent (Polyplus Transfection,
Illkirch, France) with 10 mg of total DNA. Forty-eight hours after
transfection, cells were washed in PBS and cell lysis was performed
by incubating the cells 15 minutes at 4uCi n1 5 0mlo fl y s i sb u f f e r
(50 mM Tris?HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100; 16protease inhibitor mixture and 16phosphatase
inhibitor cocktail). Cellular debris were removed by centrifugation at
100006g for 10 minutes. Equivalent amounts of protein were
loaded on 10% SDS-PAGE gel and analyzed by western blot using
polyclonal rabbit anti-Phospho-ERK1/2 (1/1000), anti-ERK1/2
(1/1000),anti-Phospho-Akt(1/1000)oranti-Akt(1/1000)antibodies
(Biotechnology, Santa-Cruz, CA).
Cell immunofluorescence analysis
Five to ten thousand MCF7, MCF10A, HeLa or MDCK cells
were plated on coverslips in 24-well plates and transfected using
JetPEI
TM transfection reagent (Polyplus Transfection, Illkirch,
France) with 3 mg of the plasmids of interest. After 24 hours, cells
were washed in PBS, fixed for 5 minutes at room temperature in
4% paraformaldehyde in PBS, and permeabilized 2 times for
10 minutes with 0.1% Triton X-100 in PBS. To visualize
endogenous TRAF4 with 2H1 antibody, cells were fixed in 50%
Methanol/50% Acetone for 15 minutes at 220uC; no permeabi-
lization was needed in this case. After blocking with 1% BSA
fraction V in PBS for 30 minutes, cells were incubated at room
temperature with the primary antibodies 2H1 (1/500), anti-Flag
(1/10000), anti-E-cadherin (1/250), anti-desmoplakin (1/5; Man-
nheim Boehringer, Germany), anti-occludin (1/250; Mannheim
Boehringer, Germany), anti-ZO-1 (1/50; Zymed Laboratories Inc,
CA), for 1 hour. Cells were washed 3 times in PBS and incubated
for 1 hour with the appropriate secondary antibodies (1/400).
Cy3- or Cy5-conjugated affinity-purified goat anti-mouse IgG or
Alexa Fluor 488-conjugated goat anti-rabbit IgG were purchased
from Jackson ImmunoResearch (West Grove, PA), Amersham
Biosciences, and Molecular Probes (Eugene, OR), respectively.
Cells were washed 3 times in PBS, and nuclei were counterstained
with Hoechst 33258 dye. Slides were mounted in Vectashield
(Polysciences Inc., Warrington, PA). Observation were made with
a fluorescence microscope (Leica DMLB 30T, Leica Micro system,
Wetzlar Germany) or confocal microscopes (Leica SP1 and Leica
SP2 UV, Leica Microsystem).
Human breast tissue analysis
Tissues were fixed in phosphate buffered formalin (4%).
Immunohistochemical analysis was performed on paraffin-embed-
ded human breast tissue sections using a peroxidase-antiperox-
idase system (DAKO, Carpinteria, CA), as described previously
[9]. Ten in situ carcinoma, and more than 20 samples of invasive
carcinomas were studied and showed similar results.
Normal human breast epithelium studied using immunofluo-
rescence were localized in the distal part of the paraffin-embedded
biopsies of human breast carcinomas. More than 10 were tested.
They were treated using the antibodies used for cell analysis (see
above), as described previously [36]. Observations were made with
a confocal microscopes (Leica SP1 and Leica SP2-MP, Leica
Microsystem).
Fluorescence recovery after photobleaching (FRAP)
The open reading frame of TRAF4 was cloned into the pEYFP-
N1 vector (Clontech) to generate a TRAF4-EYFP fusion protein
expression vector. MDCK cells were plated on glass-bottomed
dishes (MatTek, Ashland, MA), transfected (JetPEI
TM technic
described above) with fluorescent EYFP-TRAF4. 72 hours later,
the cells were incubated in a temperature controlled chamber
(37uC), mounted on an inverted Leica SP2 AOBS MP microscope.
Bleaching was done with an argon laser (458, 476, 488, 514 nm).
Images were collected every 3.3 seconds during 150 s. Images
were then averaged and the fluorescence intensity in the bleach
zone was measured in the time series. The fluorescence intensity
was corrected for background. The fluorescence signal was
normalized to the change in total fluorescence using the following
formula: Irelt=(T 06It)/(Tt6I0) [37]. T0 total cellular fluorescence
intensity during prebleach, Tt the total cellular fluorescence
intensity at timepoint t, I0 the fluorescence intensity in the region
of interest during pre-bleach and It the fluorescence intensity in the
region of interest at timepoint t. Cytoplasmic fluorescence was
normalized to 100 at time zero.
Supporting Information
Movie S1 MDCK cells transfected with EYFP-TRAF4 for
72 hours were analyzed by FRAP. One representative cell
expressing EYFP-TRAF4 is shown. All TJs were bleached and
pictures were taken every 3.3 s. EYFP-TRAF4 rapidly recovers
within the bleached area indicating that TRAF4 is a highly mobile
protein.
Found at: doi:10.1371/journal.pone.0003518.s001 (2.03 MB
MPG)
Movie S2 MDCK cells transfected with EYFP-TRAF4 for
72 hours were analyzed by FRAP. Two representative cells
expressing EYFP-TRAF4 are shown. Pictures were taken every
3.3 s. While the fluorescence intensity remains constant in the
cytoplasm of the unbleached cell (upper cell) it decreases over time
in the bleached cell (lower cell), showing that cytoplasmic EYFP-
TRAF4 molecules are mobilized to the bleached area during
recovery. Thus TRAF4 shuttles very rapidly between the
cytoplasm and TJs.
Found at: doi:10.1371/journal.pone.0003518.s002 (2.03 MB TIF)
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